A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab (MK-3475), following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.

• Condition: Carcinoma, Non-Small Cell Lung
• Intervention:
  • Drug: Pembrolizumab
• Phase: Phase 2

For full description, see www.clinicaltrials.gov.

Read news release about this trial.

Watch a video about this trial:

Manuscripts/Articles:

• Durm, GA, Jabbour, SK, Althouse, SK, Liu, Z, Sadiq, AA, Zon, RT, Jalal, SI, Kloecker, GH, Williamson, MJ, Reckamp, KL, Langdon, RM, Kio, EA, Gentzler, RD, Adesunloye, BA, Harb, WA, Walling, RV, Titzer, ML, Hanna, NH. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN14-179. Cancer. 2020: 126: 4353– 4361. https://doi.org/10.1002/cncr.33083. See abstract.
• Bilal Anouti, Sandra Althouse, Greg Durm, Nasser Hanna. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179. Clinical Lung Cancer, Volume 21, Issue 3, 2020, Pages 288-293, ISSN 1525-7304, https://doi.org/10.1016/j.cllc.2019.06.009. See abstract.
• S.S. Ahmed, G.A. Durm, J. Donatelli, Y. Liu, H. Yao, C. Desrosiers, Z. Liu, F.M. Kong, N. Hanna. Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial. Journal of Thoracic Oncology, Volume 12, Issue 11, S1552. See abstract.

Abstracts/Posters/Presentations:

• N Shukla, SK Althouse, AA Sadiq, SI Jalal, SK Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna, GA Durm. The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179. Presented as a poster at the 2020 American Society of Clinical Oncology Annual Meeting. See abstract.
• G. Durm, S. Althouse, A. Sadiq, S. Jalal, S. Jabbour, R. Zon, G. Kloecker, M. Williamson, K. Reckamp, E. Kio, R. Langdon, B. Adesunloye, R. Gentzler, W. Harb, R. Walling, C. Yeon, M. Koczywas, N. Hanna. P1.18-05 ChemoXRT w/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Presented at the IASLC 2019 World Conference on Lung Cancer. See abstract.
• GA Durm, SK Althouse, AA Sadiq, SI Jalal, S Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Presented at the Oral Abstract Session at the 2018 ASCO Annual Meeting on Monday, June 4, 2018. J Clin Oncol 36, 2018 (suppl; abstr 8500). See abstract.
• G.A. Durm, E.A. Kio, W.B. Fisher, M.L. Titzer, S.Jabbour, T.Breen, Z.Liu, N.H. Hanna. Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179. Accepted as a publication-only abstract at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr e20025). See abstract.